NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
Clinical Trials
14 trialsNCT04891744 2021-05-18
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
Phase 1/2 Unknown
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT02248428 2017-09-06
CTd
Jinling Hospital, China
Phase 3 Unknown
NCT02467647 2015-06-10
HLJDT-2016
Wuhan University
Phase 1 Unknown
NCT00028886 2013-09-17
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT01134484 2012-07-20
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 3 Unknown
NCT01532856 2012-02-15
Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years
Grupo de Estudos Multicentricos em Onco-Hematologia
Phase 3 Unknown
NCT01114048 2011-09-22
KMM-97
Chonnam National University Hospital
Phase 2 Unknown
NCT01249690 2010-11-30
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Second Military Medical University
Phase 4 Unknown
NCT00124813 2010-02-02
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
University Hospital, Bonn
Phase 2 Unknown
NCT00438841 2009-03-13
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00349115 2008-05-06
TCD Followed by autoSCT for Newly Diagnosed MM Patients
Korean Multiple Myeloma Working Party
Phase 2 Unknown
NCT00319865 2006-04-27
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Korean Multiple Myeloma Working Party
Phase 2 Unknown